---
figid: PMC4201220__bt-22-371f2
figtitle: Wnt/Beta-catenin signaling pathways and a strategy for the phenotype-based
  drug identification using C
organisms:
- Caenorhabditis elegans
- Homo sapiens
organisms_ner:
- Caenorhabditis elegans
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4201220
filename: bt-22-371f2.jpg
figlink: /pmc/articles/PMC4201220/figure/f2-bt-22-371/
number: F2
caption: Wnt/β-catenin signaling pathways and a strategy for the phenotype-based drug
  identification using C. elegans mutants. (A) Without signaling (absence of ligand),
  negative regulators (CKIα, GSK3β, Axin, and APC) phosphorylate β-catenin, and then
  ubiquitinated and degraded by the proteasome. (B) With signaling (presence of ligand),
  stabilized β-catenin in cytoplasm is translocated into nucleus and activate the
  expression of target genes. (C) Genetic pathway for control DTC fate specification
  (see text for explanation). (D) Wild-type hermaphrodite has two DTCs. lag-2::GFP
  reporter is strongly expressed in DTCs (see green). (E) Loss of Wnt/β-catenin signaling
  affects DTC fate specification. (F) Activation of Wnt/β-catenin signaling contributes
  to extra DTC formation. (G) Strategy for the phenotype-based identification of drugs
  that either inhibit or activate Wnt/β-catenin signaling using C. elegans mutants.
papertitle: 'Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery
  and Therapeutic Target Identification.'
reftext: Robert A. Kobet, et al. Biomol Ther (Seoul). 2014 Sep;22(5):371-383.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.5701585
figid_alias: PMC4201220__F2
figtype: Figure
redirect_from: /figures/PMC4201220__F2
ndex: c6115a99-df38-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4201220__bt-22-371f2.html
  '@type': Dataset
  description: Wnt/β-catenin signaling pathways and a strategy for the phenotype-based
    drug identification using C. elegans mutants. (A) Without signaling (absence of
    ligand), negative regulators (CKIα, GSK3β, Axin, and APC) phosphorylate β-catenin,
    and then ubiquitinated and degraded by the proteasome. (B) With signaling (presence
    of ligand), stabilized β-catenin in cytoplasm is translocated into nucleus and
    activate the expression of target genes. (C) Genetic pathway for control DTC fate
    specification (see text for explanation). (D) Wild-type hermaphrodite has two
    DTCs. lag-2::GFP reporter is strongly expressed in DTCs (see green). (E) Loss
    of Wnt/β-catenin signaling affects DTC fate specification. (F) Activation of Wnt/β-catenin
    signaling contributes to extra DTC formation. (G) Strategy for the phenotype-based
    identification of drugs that either inhibit or activate Wnt/β-catenin signaling
    using C. elegans mutants.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ceh-22
  - lin-17
  - mom-5
  - sys-1
  - dsh-2
  - mig-5
  - pop-1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - ADAR
  - DVL1P1
  - GSK3B
  - CSNK1A1
  - AXIN1
  - AXIN2
  - CTNNB1
  - APC
  - PROC
  - HNF4A
  - SYS1
  - RAC1
  - POP1
  - BVES
  - PYDC1
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - fz
  - arr
  - dsh
  - sgg
  - Axn
  - gskt
  - CkIalpha
  - arm
  - Apc
  - Apc2
  - Fs(3)Apc
  - mid
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - 'Off'
  - pan
  - 'On'
  - anchor
  - Sys1
  - Pop1
---
